Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03361969
Other study ID # PR3109
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date April 16, 2018
Est. completion date May 15, 2020

Study information

Verified date June 2021
Source Pantarhei Oncology B.V.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase IIa, double-blind, randomised, placebo-controlled, multi-center study to evaluate the effects of estetrol on testosterone suppression and quality of life in prostate cancer patients treated with an LHRH agonist. Patients will be treated with estetrol or placebo for 6 months.


Recruitment information / eligibility

Status Completed
Enrollment 63
Est. completion date May 15, 2020
Est. primary completion date May 15, 2020
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male patients with prostate cancer, qualifying for treatment with a LHRH agonist; - Age = 18 years; - Body mass index (BMI) between = 18.0 and = 35.0 kg/m2 (inclusive); - Reasonable physical and mental health as judged by the Investigator determined by physical examination, clinical laboratory assessments and vital signs; - Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1; - Life expectancy of at least 2 years. Exclusion Criteria: - Current or prior (during the last 12 months) hormonal therapy, immunotherapy or chemotherapy for prostate cancer. Allowed are 14 days concomitant treatment with an anti-androgen to prevent the flare-up, radiotherapy and low dose radiation to prevent gynecomastia; - History of deep vein thrombosis, pulmonary embolism, or cerebrovascular accident. However, patients with such history using anticoagulants for = 6 months are eligible for the study provided anticoagulant treatment is continued throughout the whole study; - History of myocardial infarction or a coronary vascular procedure (e.g. percutaneous coronary intervention, coronary artery bypass graft). However, patients with such history using anticoagulants for = 6 months are eligible for the study provided anticoagulant treatment is continued throughout the whole study; - Patients who have unstable angina or clinical congestive heart failure; - A defect in the blood coagulation system, assessed at screening: deficiencies in AT-III, protein C and protein S and elevated factor VIII; - Mutation in coagulation factor II and/or positive for factor V Leiden, assessed at screening; - Diabetes mellitus with poor glycaemic control in the past 6 months (haemoglobin A1c (HbA1c) above 7.5%); - Known primary hyperlipidaemias (Fredrickson); - Disturbance of liver function: cholestatic jaundice, a history of jaundice due to previous estrogen use, Rotor syndrome and Dubin-Johnson syndrome; - Known porphyria; - Uncontrolled hypertension, i.e. systolic blood pressure 160 mmHg and/or diastolic blood pressure 100 mmHg in the last 6 months with or without medication.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Estetrol
estetrol formulated in tablets
Placebo Oral Tablet
placebo tablets

Locations

Country Name City State
Netherlands Noord West Ziekenhuis Alkmaar
Netherlands Andros Men's Health Institutes Arnhem Gelderland
Netherlands St Antonius Ziekenhuis Nieuwegein
Netherlands CWZ Nijmegen
Netherlands Antonius Ziekenhuis Sneek
Netherlands Isala Zwolle Zwolle

Sponsors (1)

Lead Sponsor Collaborator
Pantarhei Oncology B.V.

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in total testosterone levels between treatment groups Serum concentrations of total testosterone will be listed and summarized descriptively by treatment group. Nadir and time to nadir will be described using summary statistics. 168 days
Primary Difference in free testosterone levels between treatment groups Serum concentrations of free testosterone will be listed and summarized descriptively by treatment group. Nadir and time to nadir will be described using summary statistics. 168 days
Primary Difference in mean daily hot flushes score between treatment groups The number and severity in hot flushes will be assessed by means of a diary in which the patients records his hot flushes for 7 days. 168 days
Secondary Change from baseline in endocrine parameters, adrenal androgen, dihydrotestosterone (DHT) and Sex Hormone Binding Globulin (SHBG) Effects on endocrine parameters (Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) and Estradiol (E2), adrenal androgens (Dehydroepiandrosterone sulfate (DHEAS)), dihydrotestosterone (DHT) and SHBG will be evaluated. Actual values at baseline and at the scheduled visits, as well as change from baseline values at the post-baseline visits will be described using summary statistics and graphs. Difference between the treatment groups will be evaluated. 168 days
Secondary Change from baseline in prostate-specific antigen (PSA) response Effects on PSA response will be evaluated. Actual values at baseline and at the scheduled visits, as well as change from baseline and percentage change from baseline values at the post-baseline visits will be described using summary statistics and graphs. Nadir and time to nadir will be described using summary statistics. Difference between the treatment groups will be evaluated. 168 days
Secondary Questionnaire on Quality of Life Effects on FACT-P questionnaire will be evaluated. FACT-P includes a 27-item "core" quality of life measure (FACT-G) grouped into 4 sub-scales: physical, social/family, emotional, and functional well-being. The prostate cancer-specific subscale contains an additional 12 items; 10 of which are prostate cancer specific physical problems. Items are rated on a 5-item Likert scale, from 0, "not at all", to 4, "very much". Total range of scores is from 0 - 156. Higher scores indicate higher degree of functioning and better quality of life.
Total FACT-P scores, FACT-P general health subscale score (FACT-G) total score and all FACT-P subscale scores will be described at the scheduled visits using summary statistics and graphs. Differences between the treatment groups will be evaluated.
168 days
Secondary Change from baseline in lipids Effects on total cholesterol, triglycerides, High Density Lipoprotein (HDL) cholesterol and Low Density Lipoprotein (LDL) cholesterol will be evaluated. Actual values at baseline and at the schedule visits as well as change from baseline values at the post-baseline visits will be described using summary statistics and graphs. Differences between the treatment groups will be evaluated. 168 days
Secondary Change from baseline in bone turnover markers Effects on bone turnover markers osteocalcin and type I collagen telopeptide (CTX-1) will be evaluated. Actual values at baseline and at the schedule visits as well as change from baseline values at the post-baseline visits will be described using summary statistics and graphs. Differences between the treatment groups will be evaluated. 168 days
See also
  Status Clinical Trial Phase
Completed NCT03982095 - Survey on Lifestyle, Perceived Barriers and Development of Change in Patients With Prostate Cancer
Recruiting NCT05667636 - Early Salvage Stereotactic Radiotherapy for Biochemical Failure After RP Phase 2
Terminated NCT01996696 - Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate Phase 2
Completed NCT01431391 - Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer Phase 2
Completed NCT03289130 - Dietary Factors and Racial Disparities in Prostate Cancer Aggressiveness
Recruiting NCT04462926 - Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed N/A
Completed NCT00001446 - A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer Phase 2
Completed NCT02729103 - Treatment Patterns in Metastatic Prostate Cancer N/A
Completed NCT00956228 - Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer Phase 1/Phase 2
Completed NCT00126854 - High Field Magnetic Resonance Spectroscopy Imaging for Follow Up of Prostate Cancer Post Brachytherapy Implantation N/A
Completed NCT00247312 - Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial Phase 3
Completed NCT00174863 - Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer Phase 2
Terminated NCT04221828 - Trial of NanoPac Focal Therapy for Prostate Cancer Phase 2
Completed NCT00001266 - A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma Phase 2
Active, not recruiting NCT03935282 - Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors N/A
Completed NCT03693742 - MSG Use With 18F-DCFPyL PET/CT Imaging N/A
Recruiting NCT06236789 - Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer
Completed NCT02966535 - The Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep Trendelenburg Position : A Crossover Randomized Clinical Trial N/A
Completed NCT02977143 - Positive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiveness in Robot-assisted Laparoscopic Surgery N/A
Completed NCT00252460 - CT/MRI Co-registration Prostate Cancer Phase 1